Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.

JCO oncology practice - 1 Jul 2026

Delasos Lukas, Hassan Khaled A

Abstract excerpt

The treatment landscape of non-small cell lung cancer (NSCLC) has advanced considerably in the past two decades, driven largely by molecular profiling and the development of targeted therapies. Among oncogenic drivers, mutations in the epidermal growth factor receptor (EGFR) have proven to be particularly significant, with the introduction of tyrosine kinase inhibitors (TKIs) revolutionizing management. While...

Topics

Join the communities discussing this publication.

Acrylamides
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
ROS1 gene
Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Identifiers

PMID: 41730152
DOI: 10.1200/OP-25-01061

Genes

EGFR
ALK
RET
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.PMID 41730152Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.Semantic proximity Read ↗

An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update.Semantic proximity Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Osimertinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies.Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.Semantic proximity Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.